JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Plasma Epstein-Barr Virus DNA Temporal Clearance Pattern During Induction-Concurrent (Chemo)Radiation Therapy for Risk Stratification in Nasopharyngeal Carcinoma

  • 0Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
International Journal of Radiation Oncology, Biology, Physics +

|

April 9, 2025

|

April 9, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Tracking Epstein-Barr virus (EBV) DNA levels during treatment reveals distinct patterns that predict nasopharyngeal carcinoma (NPC) patient outcomes. Early EBV DNA elimination during chemotherapy offers the best prognosis, while resurgence indicates higher risk.

Area Of Science

  • Oncology
  • Virology
  • Biomarker Research

Background

  • Plasma Epstein-Barr virus (EBV) DNA is a key biomarker for nasopharyngeal carcinoma (NPC).
  • Previous studies often analyzed EBV DNA at a single time point, missing the prognostic value of its clearance patterns during treatment.

Purpose Of The Study

  • To investigate the prognostic significance of different EBV DNA clearance patterns during induction-concurrent chemoradiation therapy (chemoRT) in NPC patients.
  • To identify distinct temporal EBV DNA trajectories and their association with progression-free survival (PFS).

Main Methods

  • Retrospective analysis of 2203 nonmetastatic NPC patients undergoing induction-concurrent chemoRT.
  • EBV DNA levels were measured at baseline (T0), end of induction chemotherapy (T1), and end of RT (T2), categorized as detectable (D) or undetectable (U).
  • Association between five identified EBV DNA patterns (U-U-U, D-U-U, D-D-U, D-D-D, and resurgence patterns) and PFS was analyzed.

Main Results

  • Five EBV DNA patterns were identified: U-U-U (7.3%), D-U-U (42.8%), D-D-U (35.0%), D-D-D (11.7%), and resurgence (3.3%).
  • The D-U-U pattern (elimination after induction chemotherapy) showed superior 5-year PFS (82.9%) compared to D-D-U (75.9%), D-D-D (52.5%), and resurgence patterns (72.5%).
  • Resurgence patterns, particularly D-U-D, were associated with advanced stage (III-IV) NPC and lower PFS.

Conclusions

  • Temporal EBV DNA clearance patterns during induction-concurrent chemoRT offer valuable prognostic information for NPC.
  • These patterns can help identify high-risk patients and guide personalized treatment strategies.
  • Careful consideration is needed for reduced-intensity therapy in patients with advanced disease showing EBV DNA undetectability post-induction chemotherapy due to potential resurgence.